- - --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
Filing No. 1 for the month of April, 1999
Visible Genetics Inc.
--------------------------
(Exact name of Registrant)
700 Bay Street, Suite 1000, Toronto ON, Canada M5G 1Z6
------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F
Form 20-F |X| Form 40-F |_|
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes |_| No |X|
- - --------------------------------------------------------------------------------
<PAGE>
VISIBLE GENETICS INC.
The Company has announced that it has entered into an agreement with Roche
Diagnostics S.L. (Roche) whereby Roche will be the exclusive distributor in
Spain and Portugal of the Company's OpenGene(TM) automated DNA sequencing system
and GeneKits(TM). The agreement is for a period of three years and has
provisions that guarantee minimum annual revenues over that period to the
Company
Roche, headquartered in Basel, Switzerland, is a world leader in
research-based healthcare, with principal business in pharmaceuticals,
diagnostics, vitamins, and fragrances and flavors.
On or about April 16, 1999, the Company issued a press release with
respect to the foregoing.
The Company hereby incorporates by reference the text of this Form 6-K
(but not the Exhibit hereto) into the Company's Registration Statements on Form
F-3 (File Nos. 333-67607 and 333-68939).
Exhibit 1. Press release - "Visible Genetics Inc. and Roche Diagnostics
S.L. enter exclusive distribution and marketing agreement for VGI products in
Spain and Portugal."
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: April 16, 1999 By: /s/ Jeffrey D. Sherman
----------------------
Name: Jeffrey D. Sherman
Title: Vice President, Finance and C.F.O.
3
[LETTERHEAD OF VISIBLE GENETICS INC.]
- - --------------------------------------------------------------------------------
For Immediate Release
Contacts:
Bruno Maruzzo David Sassoon (212)527-7453
Visible Genetics Inc. (416) 813-3271 Rowland-Wang Healthcare
Antonio Ferrer Roanne Argyle (416)968-7311
Roche Diagnostics Spain (+34 933067100) Argyle Rowland Worldwide
VISIBLE GENETICS INC. AND ROCHE DIAGNOSTICS S.L. ENTER EXCLUSIVE DISTRIBUTION
AND MARKETING AGREEMENT FOR VGI PRODUCTS IN SPAIN AND PORTUGAL
TORONTO, CANADA, April 16, 1999 - Visible Genetics Inc. (VGI, Nasdaq:VGIN) and
Roche Diagnostics S.L. (Roche) have entered into an agreement whereby Roche will
be the exclusive distributor in Spain and Portugal of VGI's OpenGene(TM)
automated DNA sequencing system and GeneKits(TM), including HIV-1, Hep C, Hep B,
and TB TruGene(TM) assays in the diagnostics market. The agreement is for a
period of three years and has provisions that guarantee minimum annual revenues
over that period to VGI.
"This agreement represents an important milestone for VGI and is the first of
many in our worldwide strategy of working with the best healthcare partner in
each geographical market. Overnight, we have placed in the field, a talented,
high-energy team of approximately 200 experts selling, marketing and supporting
VGI products. In addition, the Roche team will help bring VGI's products to
early commercialization by working with VGI on the extensive clinical trial
program we already have in place in Europe," comments Dr. Chalom Sayada, Vice
President Europe for Visible Genetics. "For example, their involvement in our
VIRADAPT, VIGILANCE I, and VIGILANCE II studies will help focus the use of
genotyping in the reduction of HIV-1 infection and help improve the management
of this terrible disease," Dr. Sayada continued.
1
<PAGE>
"We believe this collaboration allows us to offer a complete solution to the
physician for the diagnosis and monitoring of their infectious disease patients,
particularly those patients suffering with the HIV-1 and hepatitis viruses,"
says Joachim Langer, General Manager of Roche Diagnostics Spain. "We believe
that this complementary product offering will bring added value to our
customers. For example, Roche can now provide doctors with the immunochemistry
tests to detect and confirm the presence of the HIV-1 virus; quantitate the
amount of virus ("viral load") in a patient's blood via PCR (polymerase chain
reaction technology) testing; and then sequence the resistant HIV-1 mutations a
patient has in order to better predict the effectiveness of their antiviral drug
therapy," he added.
Visible Genetics Inc. manufactures and markets high performance automated DNA
sequencing systems and complete diagnostic kits for the analysis of genes linked
to disease. The Company's OpenGene(TM) system employs proprietary stratified DNA
testing and single-tube, single-step sequencing methods to significantly reduce
the time and cost involved in identifying clinically relevant genetic
information. VGI is a leader in the emerging field of pharmacogenomics that uses
genetic information to identify, analyze and treat medical conditions for the
benefit of improving patient care and reducing healthcare costs.
Roche, headquartered in Basel, Switzerland, is a world leader in research-based
healthcare, with principal business in pharmaceuticals, diagnostics, vitamins,
and fragrances and flavours. The Roche Group owns three manufacturing plants in
Spain; one for pharmaceutical products in Leganes (Madrid), another for vitamins
in San Fernando de Henares (Madrid), and a third one in fragrances and flavours
in Sant Celoni. In Spain, there are approximately 2,000 employees, and the total
invoicing in 1998 amounted to 80,000 million Pesetas.
###
